Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Efficacia e sicurezza di Nemtabrutinib (MK-1026) nei partecipanti con neoplasie ematologiche (MK-1026-003)

23 ottobre 2026 aggiornato da: Merck Sharp & Dohme LLC

Uno studio di fase 2 per valutare l'efficacia e la sicurezza di MK-1026 nei partecipanti con neoplasie ematologiche

The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM).

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This study will be performed in 2 parts: Dose Escalation and Confirmation (Part 1) and Cohort Expansion (Part 2). Following determination of the recommended phase 2 dose (RP2D) in Part 1, the study plans to proceed with Part 2 using 8 disease-specific expansion cohorts (Cohorts A to H).

Tipo di studio

Interventistico

Iscrizione (Stimato)

490

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

      • Caba, Argentina, C1114AAN
        • Reclutamento
        • FUNDALEU ( Site 0104)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 5411 48771046
      • Córdoba, Argentina, X5016KEH
        • Reclutamento
        • Hospital Privado Universitario de Córdoba ( Site 0107)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +541569634187
      • Mendoza, Argentina, M5500AYB
        • Completato
        • Fundacion Centro Oncologico de Integración Regional-Medical Oncology ( Site 0110)
    • Buenos Aires
      • Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1118AAT
        • Reclutamento
        • Hospital Aleman ( Site 0102)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +541148277000
    • Buenos Aires F.D.
      • Buenos Aires, Buenos Aires F.D., Argentina, C1431FWO
        • Reclutamento
        • Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0103)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +541152990247
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentina, S2000DEJ
        • Reclutamento
        • Fundacion Estudios Clinicos ( Site 0112)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +54 0341 238 4171
    • New South Wales
      • Sydney, New South Wales, Australia, 2747
        • Completato
        • Nepean Hospital-Nepean Cancer Care Centre ( Site 0204)
    • Victoria
      • Box Hill, Victoria, Australia, 3128
        • Reclutamento
        • Box Hill Hospital ( Site 0203)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +611300342255
    • Western Australia
      • Nedlands, Western Australia, Australia, 6009
        • Reclutamento
        • Sir Charles Gairdner Hospital ( Site 0200)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +61864573333
      • Rio de Janeiro, Brasile, 20231-050
        • Reclutamento
        • Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0300)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +552132076564
      • São Paulo, Brasile, 01321-001
        • Reclutamento
        • Hospital Paulistano - Amil Clinical Research ( Site 0311)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +551130161340
      • São Paulo, Brasile, 01321-001
        • Attivo, non reclutante
        • BP - A Beneficencia Portuguesa de São Paulo ( Site 0302)
    • São Paulo
      • São Paulo, São Paulo, Brasile, 05403-000
        • Reclutamento
        • Hospital das Clinicas FMUSP-Pesquisa Clínica Hematologia ( Site 0303)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 551145737543
    • Alberta
      • Calgary, Alberta, Canada, T2N 5G2
        • Reclutamento
        • Arthur J.E. Child Comprehensive Cancer Centre ( Site 0401)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 4035213723
    • Ontario
      • Ottawa, Ontario, Canada, K1H 8L6
        • Reclutamento
        • The Ottawa Hospital ( Site 0404)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 613 737-7700
      • Toronto, Ontario, Canada, M5G 2M9
        • Reclutamento
        • Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0406)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 416-946-2827
    • Quebec
      • Montreal, Quebec, Canada, H3T 1E2
        • Reclutamento
        • Jewish General Hospital ( Site 0400)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 5143408222 x 24572
      • Montreal, Quebec, Canada, H1T 2M4
        • Reclutamento
        • CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0403)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 5142523400
      • Hradec Králové, Cechia, 500 05
        • Reclutamento
        • Fakultni nemocnice Hradec Kralove ( Site 0601)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +420495832159
    • Brno-mesto
      • Brno, Brno-mesto, Cechia, 625 00
        • Reclutamento
        • Fakultní nemocnice Brno Bohunice-Interni hematologicka a onkologicka klinika ( Site 0600)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +420532233642
    • Anhui
      • Hefei, Anhui, Cina, 230071
        • Attivo, non reclutante
        • Anhui Provincial Hospital ( Site 2808)
    • Beijing Municipality
      • Beijing, Beijing Municipality, Cina, 100191
        • Reclutamento
        • Peking University Third Hospital-Hematology ( Site 2827)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 010-82266699
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, Cina, 400072
        • Attivo, non reclutante
        • The Second Affiliated Hospital of Chongqing Medical University ( Site 2825)
    • Guangdong
      • Guangzhou, Guangdong, Cina, 510060
        • Attivo, non reclutante
        • Sun Yat-sen University Cancer Center-Internal Medicine ( Site 2824)
    • Guangxi
      • Liuzhou, Guangxi, Cina, 545006
        • Reclutamento
        • Liuzhou People's Hospital ( Site 2817)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +8607722662950
      • Nanning, Guangxi, Cina, 530028
        • Reclutamento
        • Guangxi Medical University Cancer Hospital ( Site 2814)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +8607715323174
    • Henan
      • Zhengzhou, Henan, Cina, 450008
        • Reclutamento
        • Henan Cancer Hospital-hematology department ( Site 2802)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 0371-65588007
    • Hubei
      • Wuhan, Hubei, Cina, 430022
        • Reclutamento
        • Wuhan Union Hospital ( Site 2816)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +8618627091655
    • Hunan
      • Changsha, Hunan, Cina, 410011
        • Reclutamento
        • The Second Xiangya Hospital of Central South University ( Site 2820)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +8613975806137
      • Changsha, Hunan, Cina, 410013
        • Reclutamento
        • Hunan Cancer Hospital ( Site 2822)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 0731-88651669
    • Jiangsu
      • Nanjing, Jiangsu, Cina, 210029
        • Reclutamento
        • Jiangsu Province Hospital ( Site 2823)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 025-86211033
      • Xuzhou, Jiangsu, Cina, 221000
        • Completato
        • The Affiliated Hospital of Xuzhou Medical College ( Site 2818)
    • Jiangxi
      • Nanchang, Jiangxi, Cina, 330006
        • Reclutamento
        • The First Affiliated Hospital of Nanchang University ( Site 2815)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 13970038386
    • Jilin
      • Changchun, Jilin, Cina, 130021
        • Reclutamento
        • The First Hospital of Jilin University-Hematology ( Site 2803)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 0431-88786014
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Cina, 200032
        • Reclutamento
        • Fudan University Shanghai Cancer Center ( Site 2801)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +8602164175590
      • Shanghai, Shanghai Municipality, Cina, 200040
        • Reclutamento
        • Huashan Hospital, Fudan University ( Site 2821)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 021-52889999
    • Sichuan
      • Chengdu, Sichuan, Cina, 610041
        • Reclutamento
        • West China Hospital Sichuan University ( Site 2810)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +86028-85422114
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Cina, 301617
        • Reclutamento
        • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Unio ( Site 2800)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +8615900265415
    • Zhejiang
      • Hangzhou, Zhejiang, Cina, 310002
        • Reclutamento
        • The First Affiliated Hospital, Zhejiang University ( Site 2826)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 057187236114
      • Seoul, Corea del Sud, 03722
        • Reclutamento
        • Severance Hospital Yonsei University Health System ( Site 2201)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +82222281972
      • Seoul, Corea del Sud, 06351
        • Reclutamento
        • Samsung Medical Center ( Site 2200)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +82234106548
    • Central Jutland
      • Aarhus N, Central Jutland, Danimarca, 8200
        • Completato
        • Aarhus University Hospital ( Site 0702)
    • North Denmark
      • Aalborg, North Denmark, Danimarca, 9000
        • Reclutamento
        • Aalborg Universitetshospital ( Site 0703)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +45 97660000
    • Region Sjælland
      • Koege, Region Sjælland, Danimarca, 4600
        • Reclutamento
        • Sjællands Universitetshospital Køge ( Site 0701)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +45 46323200
    • Region Syddanmark
      • Odense C, Region Syddanmark, Danimarca, 5000
        • Completato
        • Odense University Hospital ( Site 0705)
      • Paris, Francia, 75010
        • Reclutamento
        • Hopital Saint Louis ( Site 0805)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +33142499236
    • Alpes-Maritimes
      • Nice, Alpes-Maritimes, Francia, 06202
        • Reclutamento
        • Centre Hospitalier Universitaire de Nice - Hôpital l'Archet ( Site 0810)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +33 4 92 03 57 85
    • Auvergne-Rhône-Alpes
      • Pierre-Bénite, Auvergne-Rhône-Alpes, Francia, 69495
        • Reclutamento
        • Centre Hospitalier Lyon-Sud ( Site 0804)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +33478864348
    • Bouches-du-Rhone
      • Marseille, Bouches-du-Rhone, Francia, 13009
        • Reclutamento
        • Institut Paoli-Calmettes ( Site 0803)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +33491223537
    • Yvelines
      • Le Chesnay, Yvelines, Francia, 78150
        • Completato
        • Centre Hospitalier de Versailles ( Site 0809)
    • Baden-Wurttemberg
      • Ulm, Baden-Wurttemberg, Germania, 89081
        • Reclutamento
        • Universitaetsklinikum Ulm. ( Site 0906)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: + 49 731 500 45901
    • North Rhine-Westphalia
      • Cologne, North Rhine-Westphalia, Germania, 50937
        • Reclutamento
        • Universitaetsklinikum Koeln ( Site 0901)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +4922147897046
      • Siegen, North Rhine-Westphalia, Germania, 57072
        • Completato
        • St. Marien-Krankenhaus Siegen ( Site 0914)
    • Saxony
      • Dresden, Saxony, Germania, 01307
        • Reclutamento
        • Universitaetsklinikum Carl Gustav Carus ( Site 0902)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 0049 351 458 5692
      • Dublin, Irlanda, Dublin 9
        • Reclutamento
        • Beaumont Hospital ( Site 2900)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +35318092010
      • Limerick, Irlanda, V94 F858
        • Attivo, non reclutante
        • University Hospital Limerick ( Site 2903)
      • Afula, Israele, 1834111
        • Reclutamento
        • Ha Emek Medical Center ( Site 1305)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 972-46494052
      • Beersheba, Israele, 8410101
        • Reclutamento
        • Soroka Medical Center ( Site 1307)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +97286403827
      • Haifa, Israele, 3109601
        • Reclutamento
        • Rambam Medical Center ( Site 1301)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +97247772547
      • Jerusalem, Israele, 9112001
        • Reclutamento
        • Hadassah Ein Karem Jerusalem ( Site 1300)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +97226778180
      • Ramat Gan, Israele, 5262001
        • Reclutamento
        • Chaim Sheba Medical Center ( Site 1302)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +97235308401
      • Rehovot, Israele, 76100
        • Reclutamento
        • Kaplan Medical Center ( Site 1304)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +97289441726
      • Tel Aviv, Israele, 6423906
        • Reclutamento
        • Sourasky Medical Center ( Site 1303)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +97236973782
      • Bari, Italia, 70124
        • Completato
        • Istituto Tumori Giovanni Paolo II ( Site 1409)
      • Bologna, Italia, 40138
        • Reclutamento
        • A.O. Universitaria Policlinico S. Orsola-Malpighi ( Site 1400)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +390516363680
      • Brescia, Italia, 25123
        • Reclutamento
        • ASST Spedali Civili di Brescia ( Site 1408)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +39 0303996416
      • Milan, Italia, 20132
        • Reclutamento
        • IRCCS Ospedale San Raffaele ( Site 1402)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 00390226434797
      • Naples, Italia, 80131
        • Reclutamento
        • Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1403)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +39 0815903 382
      • Pavia, Italia, 27100
        • Reclutamento
        • Fondazione IRCCS Policlinico San Matteo ( Site 1407)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +39 0382503084
      • Reggio Emilia, Italia, 42123
        • Reclutamento
        • IRCCS - Arcispedale Santa Maria Nuova ( Site 1405)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +39 0522295654
      • Roma, Italia, 00161
        • Completato
        • Policlinico Umberto I ( Site 1404)
    • Lesser Poland Voivodeship
      • Krakow, Lesser Poland Voivodeship, Polonia, 30-727
        • Reclutamento
        • Pratia MCM Krakow ( Site 1601)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 48 12 2954135
    • Lower Silesian Voivodeship
      • Wroclaw, Lower Silesian Voivodeship, Polonia, 50-367
        • Completato
        • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu ( Site 1606)
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Polonia, 02-781
        • Reclutamento
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Kilinka Onkologii I Hematologii ( Site 1608)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +48225462223
    • Opole Voivodeship
      • Opole, Opole Voivodeship, Polonia, 45-061
        • Completato
        • Szpital Wojewódzki w Opolu-Hematology Department ( Site 1607)
    • Pomeranian Voivodeship
      • Gdynia, Pomeranian Voivodeship, Polonia, 81-519
        • Completato
        • Szpitale Pomorskie Sp. z o.o. ( Site 1600)
      • Manchester, Regno Unito, M20 4BX
        • Reclutamento
        • The Christie NHS Foundation Trust ( Site 2602)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 01619561217
    • Bristol, City of
      • Bristol, Bristol, City of, Regno Unito, BS2 8ED
        • Reclutamento
        • Bristol Haematology and Oncology Centre ( Site 2610)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 01173426733
    • England
      • Nottingham, England, Regno Unito, NG5 1PF
        • Reclutamento
        • Nottingham University Hospitals NHS Trust. City Hospital Campus ( Site 2601)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +441159691169
      • Windsor, England, Regno Unito, SL4 3HD
        • Reclutamento
        • GenesisCare - Windsor ( Site 2608)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +447989474250
    • London, City of
      • London, London, City of, Regno Unito, W1G 6AD
        • Reclutamento
        • Sarah Cannon Research Institute UK ( Site 2612)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 02032195234
    • Oxfordshire
      • Oxford, Oxfordshire, Regno Unito, OX4 6LB
        • Reclutamento
        • GenesisCare - Oxford ( Site 2607)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +447989474250
    • Suffolk
      • Newmarket, Suffolk, Regno Unito, CB8 7XN
        • Reclutamento
        • GenesisCare - Cambridge ( Site 2611)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 01223 655145
    • Surrey
      • Sutton, Surrey, Regno Unito, SM2 5PT
        • Reclutamento
        • The Royal Marsden NHS Foundation Trust. ( Site 2606)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 020 8642 6011
      • Brasov, Romania, 500052
        • Reclutamento
        • Centrul de Diagnostic si Tratament Oncologic Brasov ( Site 1802)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 0729075567
      • Iași, Romania, 700483
        • Reclutamento
        • Institutul Regional de Oncologie Iasi ( Site 1801)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 40374278811
    • Bucharest
      • Bucharest, Bucharest, Romania, 030171
        • Reclutamento
        • Spitalul Clinic Colțea ( Site 1805)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 0040213874100
    • Constanța County
      • Ovidiu, Constanța County, Romania, 905900
        • Completato
        • Ovidius Clinical Hospital ( Site 1804)
      • Alicante, Spagna, 03010
        • Reclutamento
        • Hospital General Universitario de Alicante ( Site 2007)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 965 93 30 00
      • Barcelona, Spagna, 08035
        • Reclutamento
        • Hospital Universitari Vall d'Hebron ( Site 2001)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +34934893806
      • Madrid, Spagna, 28041
        • Reclutamento
        • Hospital Universitario 12 de Octubre ( Site 2003)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +34917792809
      • Madrid, Spagna, 28222
        • Reclutamento
        • Hospital Puerta de Hierro ( Site 2009)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +34911916000
    • Barcelona
      • L'Hospitalet de Llobregat, Barcelona, Spagna, 08908
        • Reclutamento
        • Instituto Catalan de Oncologia ICO - Hospital Duran i Reynals ( Site 2000)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +34932607750
    • Castille and León
      • Salamanca, Castille and León, Spagna, 37007
        • Reclutamento
        • Hospital Universitario de Salamanca ( Site 2002)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 34923 29 11 00x55974
    • La Coruna
      • A Coruña, La Coruna, Spagna, 15006
        • Reclutamento
        • CHUAC-Complejo Hospitalario Universitario A Coruña ( Site 2005)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 34981178000
    • Arkansas
      • Springdale, Arkansas, Stati Uniti, 72762
        • Reclutamento
        • Highlands Oncology Group ( Site 2728)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 479-872-8130
    • California
      • La Jolla, California, Stati Uniti, 92093-0698
        • Reclutamento
        • University of California San Diego Moores Cancer Center ( Site 2717)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 858-534-5201
      • Torrance, California, Stati Uniti, 90502
        • Completato
        • Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site 2724)
    • Colorado
      • Denver, Colorado, Stati Uniti, 80218
        • Reclutamento
        • Colorado Blood Cancer Institute ( Site 2726)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 720-754-4800
    • Kentucky
      • Louisville, Kentucky, Stati Uniti, 40202
        • Completato
        • The University of Louisville, James Graham Brown Cancer Center ( Site 2729)
    • Minnesota
      • Rochester, Minnesota, Stati Uniti, 55905
        • Attivo, non reclutante
        • Mayo Clinic - Rochester ( Site 2706)
    • New Jersey
      • East Brunswick, New Jersey, Stati Uniti, 08816
        • Reclutamento
        • Astera Cancer Care ( Site 2732)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 732-672-6405
      • Hackensack, New Jersey, Stati Uniti, 07601
        • Reclutamento
        • John Theurer Cancer Center at Hackensack University Medical Center ( Site 2704)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 551-996-3003
    • North Dakota
      • Fargo, North Dakota, Stati Uniti, 58102
        • Completato
        • Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 2708)
    • Texas
      • Dallas, Texas, Stati Uniti, 75390
        • Reclutamento
        • UT Southwestern-Harold C. Simmons Cancer Center ( Site 2730)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 972-695-9450
    • Washington
      • Spokane, Washington, Stati Uniti, 99208
        • Reclutamento
        • Medical Oncology Associates (Summit Cancer Centers) ( Site 2710)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: 509-462-2273
    • Canton Ticino
      • Bellinzona, Canton Ticino, Svizzera, 6500
        • Reclutamento
        • Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 2302)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +41918118540
    • Canton of Bern
      • Bern, Canton of Bern, Svizzera, 3010
        • Reclutamento
        • Inselspital Bern ( Site 2303)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +41316329023
      • Ankara, Turchia (Türkiye), 06590
        • Reclutamento
        • Ankara Universitesi Tip Fakultesi Cebeci Hastanesi ( Site 2400)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +903125957099
      • Istanbul, Turchia (Türkiye), 34365
        • Completato
        • VKV Amerikan Hastanesi ( Site 2403)
      • Istanbul, Turchia (Türkiye), 34381
        • Reclutamento
        • Sisli Florence Nightingale Hastanesi ( Site 2407)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +90 542 502 50 75
      • Izmir, Turchia (Türkiye), 35340
        • Attivo, non reclutante
        • Dokuz Eylül Üniversitesi-Hematology ( Site 2402)
    • Istanbul
      • Stanbul, Istanbul, Turchia (Türkiye), 34214
        • Attivo, non reclutante
        • Mega Medipol-Hematology ( Site 2406)
      • Kyiv, Ucraina, 03022
        • Reclutamento
        • National Cancer Institute ( Site 2507)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +380672091427
    • Cherkasy Oblast
      • Cherkassy, Cherkasy Oblast, Ucraina, 18009
        • Attivo, non reclutante
        • MNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( Site 2509)
    • Ivano-Frankivsk Oblast
      • Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ucraina, 76008
        • Completato
        • Communal non-profit enterprise "Regional clinical hospital o-Hematology Department ( Site 2510)
    • Lviv Oblast
      • Lviv, Lviv Oblast, Ucraina, 79044
        • Reclutamento
        • Instit. of Blood Transfusion Medicine of the National Academy ( Site 2506)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +380322352276
      • Budapest, Ungheria, 1122
        • Reclutamento
        • Orszagos Onkologiai Intezet ( Site 1200)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +3612248600
    • Baranya
      • Pécs, Baranya, Ungheria, 7624
        • Reclutamento
        • Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar ( Site 1202)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +3672536000
    • Hajdú-Bihar
      • Debrecen, Hajdú-Bihar, Ungheria, 4032
        • Reclutamento
        • Debreceni Egyetem Klinikai Kozpont ( Site 1201)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +3652255196
    • Szabolcs-Szatmár-Bereg
      • Nyíregyháza, Szabolcs-Szatmár-Bereg, Ungheria, 4400
        • Reclutamento
        • Szabolcs Szatmár Bereg Vármegyei Oktatókórház ( Site 1206)
        • Contatto:
          • Study Coordinator
          • Numero di telefono: +3642599700

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days before C1D1 (the first dose of study treatment)
  • Has a life expectancy of at least 3 months, based on the investigator assessment
  • Has the ability to swallow and retain oral medication
  • Participants who are Hepatitis B surface antigen (HBsAg)-positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization
  • Participants with history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening
  • Has adequate organ function
  • Male participants agree to refrain from donating sperm and agree to either remain abstinent from penile-vaginal intercourse as their preferred and usual lifestyle OR agree to use contraception, during the intervention period and for at least the time required to eliminate the study intervention after last dose of study intervention
  • Female participants assigned female sex at birth who are not pregnant or breastfeeding are eligible to participate if not a participant of childbearing potential (POCBP), or if a POCBP they either use a contraceptive method that is highly effective OR remain abstinent from penile-vaginal intercourse as their preferred and usual lifestyle during the intervention period and for at least to eliminate study intervention after the last dose of study intervention
  • Participants with Human immunodeficiency virus (HIV) are eligible if they meet all of the following: the CD4 count is >350 cells/uL at screening, the HIV viral load is below the detectable level, are on a stable ART regimen for at least 4 weeks prior to study entry, and are compliant with their ART

Part 1 and Part 2 (Cohorts A to C and J)

  • Has a confirmed diagnosis of Chronic lymphocytic leukemia/ Small lymphocytic lymphoma (CLL/SLL) with

    • At least 2 lines of prior therapy (Part 1 only)
    • Part 2 Cohort A: CLL/SLL participants who are relapsed or refractory to prior therapy with a covalent, irreversible Bruton's tyrosine kinase inhibitor (BTKi), and a B-cell lymphoma 2 inhibitor (BCL2i). CLL participants must have received and failed, been intolerant to, or determined by their treating physician to be a poor phosphoinositide 3-kinase inhibitor (PI3Ki) candidate or ineligible for a PI3Ki per local guidelines
    • Part 2 Cohort B: CLL/SLL participants who are relapsed or refractory following at least 1 line of prior therapy and are BTKi treatment naive
    • Part 2 Cohort C: CLL/SLL participants with 17p deletion or tumor protein p53 (TP53) mutation who are relapsed or refractory following at least 1 line of prior therapy
    • Part 2 Cohort J: CLL/SLL participants whose disease relapsed or was refractory to prior therapy with a covalent/irreversible BTKi and BCL2i. NOTE: As of Protocol Amendment 09, at least 10 CLL/SLL participants whose disease relapsed or was refractory to prior therapy with a covalent/irreversible BTKi, BCL2i and noncovalent/reversible BTKi (all three classes of therapies are required) will be enrolled into Cohort J
    • Has active disease for CLL/SLL clearly documented to initiate therapy
    • For SLL participants in Part 2: Has evaluable core or excisional lymph node biopsy for biomarker analysis from an archival or newly obtained biopsy or bone marrow aspirate at Screening (optional for participants enrolling in Part 1)

Part 2 (Cohorts D to G)

- Has a confirmed diagnosis of and meets the following prior therapy requirements:

  • Participants with Richter's transformation who are relapsed or refractory following at least 1 line of prior therapy (Cohort D)
  • Participants with pathologically confirmed Mantle-cell lymphoma (MCL), documented by either overexpression of cyclin D1 or t (11;14), who are relapsed or are refractory to chemoimmunotherapy and a covalent irreversible BTKi (Cohort E)
  • Participants with Marginal zone lymphoma (MZL) (including splenic, nodal, and extra nodal MZL) who are relapsed or refractory to at least one prior line of systemic therapy including an anti-CD20-based regimen
  • Participants with Follicular lymphoma (FL) who are relapsed or refractory to chemoimmunotherapy and immunomodulatory agents (such as lenalidomide based regimen) (Cohort G)
  • Have measurable disease defined as at least 1 lesion that can be accurately measured in at least 2 dimensions with spiral Computed tomography (CT) scan
  • Has a lymph node biopsy for biomarker analysis from an archival or newly obtained biopsy or bone marrow aspirate (Cohort D) at Screening

Part 2 (Cohort H): confirmed diagnosis of Waldenström's macroglobulinemia (WM); participants who are relapsed or refractory to standard therapies for WM including chemoimmunotherapy and a covalent irreversible BTKi

  • Has active disease defined as 1 of the following: systemic symptoms, physical findings, laboratory abnormalities, coexisting disease
  • Has measurable disease, satisfying any of the following: at least 1 lesion that can be accurately measured in at least 2 dimensions with spiral CT scan (minimum measurement must be >15 mm in the longest diameter or >10 mm in the short axis); IgM ≥450 mg/dL; or bone marrow infiltration of 10%
  • Has fresh bone marrow aspirate or a lymph node biopsy for biomarker analysis at Screening or a lymph node biopsy from an archival

Exclusion Criteria:

  • Has active HBV/HCV infection (Part 1 and Part 2)
  • Has a history of malignancy ≤3 years before providing documented informed consent. Participants with basal cell carcinoma of skin, squamous cell carcinoma of skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potential curative therapy are not excluded. Participants with low-risk, early-stage prostate cancer (T1-T2a, Gleason score ≤6, and prostate-specific antigen <10 ng/mL) either treated with definitive intent or untreated in active surveillance with SD are not excluded
  • Has active central nervous system (CNS) disease
  • Has an active infection requiring systemic therapy
  • Has received prior systemic anti-cancer therapy within 5 half-lives or 4 weeks (if prior therapy was a monoclonal antibody) before C1D1
  • Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention
  • Has any clinically significant gastrointestinal abnormalities that might alter absorption
  • History of severe bleeding disorders

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Nemtabrutinib

Participants receive nemtabrutinib orally once daily (QD) until progressive disease (PD) or discontinuation.

Nemtabrutinib tablets administered orally QD.

Altri nomi:
  • MK-1026
  • ARQ 531

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Part 1: Number of participants experiencing dose-limiting toxicities (DLTs)
Lasso di tempo: Up to ~56 days (Cycles 1-2, cycle = 28 days)

DLTs will be defined as toxicities observed during the first 2 cycles (8 weeks) of Part 1 and include: Grade ≥3 nonhematologic toxicity (except Grade 3 nausea, vomiting, diarrhea, rash, fatigue, and uncontrolled hypertension which will not be considered a DLT unless lasting ≥72 hours despite optimal supportive care); Grade 4 hematologic toxicity lasting >7 days (except Grade 3 lymphocytosis, Grade 4 platelet count decreased of any duration, or Grade 3 platelet count decreased if associated with bleeding); any Grade 3 or Grade 4 nonhematologic laboratory abnormality if values result in drug-induced liver injury, or medical intervention is required, or the abnormality leads to hospitalization, or the abnormality persists for >1 week (with exceptions); missing >25% of nemtabrutinib doses as a result of drug-related adverse events (AEs) during the first 2 cycles (8 weeks); Grade 5 toxicity.

Up to ~56 days (Cycles 1-2, cycle = 28 days)
Part 1: Number of participants experiencing adverse events (AEs)
Lasso di tempo: Up to ~71 months

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants experiencing AEs will be reported for Part 1.

Up to ~71 months
Part 1: Number of participants discontinuing study treatment due to AEs
Lasso di tempo: Up to ~42 months

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants discontinuing study treatment due to an AE will be reported for Part 1.

Up to ~42 months
Part 2: Objective Response Rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria 2018 as assessed by independent central review (ICR)
Lasso di tempo: Up to ~61 months

ORR per iwCLL 2018 criteria is defined as the percentage of participants achieving a complete response (CR), complete response with incomplete bone marrow recovery (CRi), nodular partial response (nPR), or partial response (PR). CR is defined as meeting the following criteria: no lymph nodes >1.5 cm, spleen size <13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10^9/L or ≥50% increase from screening, hemoglobin >11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow.

Up to ~61 months
Part 2: ORR per Lugano criteria 2014 as assessed by ICR
Lasso di tempo: Up to ~61 months

ORR per Lugano criteria 2014 is defined as the percentage of participants achieving a CR or PR. CR defined as EITHER CR by imaging (computed tomography [CT]): all lymph nodes normal (none ≥15 mm) and normal liver and spleen OR complete metabolic response (CMR): score of 1, 2 or 3 on the 5-point scale assessing fluorodeoxyglucose (FDG) metabolic activity in lymphomatous lesions (ranging from 1=no uptake above background to 5=uptake markedly higher than liver) AND bone marrow (BM) normal by morphology. PR defined as EITHER PR by imaging (CT) with ≥50% decrease in the sum of the product of diameters [SPD] of target lesions, no worsening of nontarget lesions, no new lesions and ≥50% spleen abnormal portion OR Partial Metabolic Response (PMR) with score of 4 or 5 on the FDG 5-point scale (with no new lesions) and decreased overall uptake AND residual BM abnormalities; OR CR by imaging with residual BM abnormalities; OR PR by imaging without residual BM abnormalities.

Up to ~61 months
Part 2: ORR per International Workshop on Waldenström's Macroglobulinemia (IWWM) criteria 2014 as assessed by ICR
Lasso di tempo: Up to ~71 months

ORR per IWWM criteria 2014 is defined as the percentage of participants achieving a CR, very good partial response (VGPR), or PR. CR is defined as all lymph nodes are normal in size (none ≥15 mm), liver and spleen normal in size, serum immunoglobulin M (IgM) values in the normal range, disappearance of monoclonal protein by immunofixation (confirmation needed with a second immunofixation at any subsequent timepoint), and no histological evidence of BM involvement. VGPR is defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in the abnormal portion of the spleen (if previously abnormal), and ≥90% decrease from baseline in serum IgM, or serum IgM values in normal range. PR is defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in serum IgM, and ≥50% decrease from baseline in the abnormal portion of the spleen (if previously abnormal).

Up to ~71 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Part 1: Area Under the Curve (AUC) of Nemtabrutinib
Lasso di tempo: At designated time points (up to ~57 days)

Blood samples will be obtained at designated time points during Part 1 for the assessment of nemtabrutinib AUC (Day 1 of Cycles 1 and 2: Pre-dose, 2, 4, 6, 8, and 24 hours post-dose; Day 1 of Cycle 3: pre-dose and 2, 4, and 6 hours post-dose [up to ~57 days]). Each cycle is 28 days.

At designated time points (up to ~57 days)
Part 1: Minimum Concentration (Cmin) of Nemtabrutinib
Lasso di tempo: At designated time points (up to ~57 days)

Blood samples will be obtained at designated time points during Part 1 for the assessment of nemtabrutinib Cmin (Day 1 of Cycles 1 and 2: Pre-dose, 2, 4, 6, 8, and 24 hours post-dose; Day 1 of Cycle 3: pre-dose and 2, 4, and 6 hours post-dose [up to ~57 days]). Each cycle is 28 days.

At designated time points (up to ~57 days)
Part 1: Maximum Concentration (Cmax) of Nemtabrutinib
Lasso di tempo: At designated time points (up to ~57 days)

Blood samples will be obtained at designated time points during Part 1 for the assessment of nemtabrutinib Cmax (Day 1 of Cycles 1 and 2: Pre-dose, 2, 4, 6, 8, and 24 hours post-dose; Day 1 of Cycle 3: pre-dose and 2, 4, and 6 hours post-dose [up to ~57 days]). Each cycle is 28 days.

At designated time points (up to ~57 days)
Part 1: ORR per iwCLL criteria 2018 as assessed by ICR
Lasso di tempo: Up to ~71 months

ORR per iwCLL 2018 criteria is defined as the percentage of participants achieving a CR, CRi, nPR, or PR. CR is defined as meeting the following criteria: no lymph nodes >1.5 cm, spleen size <13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10^9/L or ≥50% increase from screening, hemoglobin >11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow.

Up to ~71 months
Part 1: Duration of Response (DOR) per iwCLL criteria 2018 as assessed by ICR
Lasso di tempo: Up to ~71 months

For participants with CR, CRi, nPR, or PR per iwCLL 2018 criteria, DOR is defined as the time from the first documented evidence of objective response until PD or death due to any cause, whichever occurs first. CR is defined as meeting the following criteria: no lymph nodes >1.5 cm, spleen size <13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10^9/L or ≥50% increase from screening, hemoglobin >11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow.

Up to ~71 months
Part 2: Number of participants experiencing AEs
Lasso di tempo: Up to ~61 months

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants experiencing AEs will be reported for Part 2.

Up to ~61 months
Part 2: Number of participants discontinuing study treatment due to AEs
Lasso di tempo: Up to ~42 months

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants discontinuing study treatment due to an AE will be reported for Part 2.

Up to ~42 months
Part 2: AUC of Nemtabrutinib
Lasso di tempo: At designated time points (up to ~57 days)

Blood samples will be obtained at designated time points during Part 2 for the assessment of nemtabrutinib AUC (Day 1 of Cycles 1, 2, and 3: Pre-dose, 2, 4, 6, hours post-dose [up to ~57 days]). Each cycle is 28 days.

At designated time points (up to ~57 days)
Part 2: Cmin of Nemtabrutinib
Lasso di tempo: At designated time points (up to ~57 days)

Blood samples will be obtained at designated time points during Part 2 for the assessment of nemtabrutinib Cmin (Day 1 of Cycles 1, 2, and 3: Pre-dose, 2, 4, 6, hours post-dose [up to ~57 days]). Each cycle is 28 days.

At designated time points (up to ~57 days)
Part 2: Cmax of Nemtabrutinib
Lasso di tempo: At designated time points (up to ~57 days)

Blood samples will be obtained at designated time points during Part 2 for the assessment of nemtabrutinib Cmax (Day 1 of Cycles 1, 2, and 3: Pre-dose, 2, 4, 6, hours post-dose [up to ~57 days]). Each cycle is 28 days.

At designated time points (up to ~57 days)
Part 2: DOR per iwCLL criteria 2018 as assessed by ICR
Lasso di tempo: Up to ~61 months

For participants with CR, CRi, nPR, or PR per iwCLL 2018 criteria, DOR is defined as the time from the first documented evidence of objective response until disease progression or death due to any cause, whichever occurs first. CR is defined as meeting the following criteria: no lymph nodes >1.5 cm, spleen size <13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10^9/L or ≥50% increase from screening, hemoglobin >11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow.

Up to ~61 months
Part 2: DOR per Lugano criteria 2014 as assessed by ICR
Lasso di tempo: Up to ~61 months

For participants with CR or PR per Lugano criteria 2014, DOR is defined as the time from the first documented evidence of objective response until PD or death due to any cause, whichever occurs first. CR defined as EITHER CR by imaging (CT): all lymph nodes normal (none ≥15 mm) and normal liver and spleen OR CMR: score of 1, 2 or 3 on the 5-point scale assessing FDG metabolic activity in lymphomatous lesions (ranging from 1=no uptake above background to 5=uptake markedly higher than liver and/or new lesions) AND BM normal by morphology. PR defined as EITHER PR by imaging (CT) with ≥50% decrease in the SPD of target lesions, no worsening of nontarget lesions, no new lesions and ≥50% spleen abnormal portion OR PMR with score of 4 or 5 on the FDG 5-point scale (with no new lesions) and decreased overall uptake AND residual BM abnormalities; OR CR by imaging with residual BM abnormalities; OR PR by imaging without residual BM abnormalities.

Up to ~61 months
Part 2: DOR per IWWM criteria 2014 as assessed by ICR
Lasso di tempo: Up to ~61 months

For participants with CR, VGPR, or PR per IWWM criteria 2014, DOR defined as the time from first documented evidence of objective response until PD or death due to any cause, whichever occurs first. CR defined as all lymph nodes normal in size (none ≥15 mm), liver and spleen normal in size, serum IgM values in normal range, disappearance of monoclonal protein by immunofixation (confirmation needed with second immunofixation at any subsequent timepoint), and no histological evidence of BM involvement. VGPR defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in abnormal portion of the spleen (if previously abnormal), and ≥90% decrease from baseline in serum IgM, or serum IgM values in normal range. PR is defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in serum IgM, and ≥50% decrease from baseline in abnormal portion of the spleen (if previously abnormal).

Up to ~61 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: Medical Director, Merck Sharp & Dohme LLC

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

5 aprile 2021

Completamento primario (Stimato)

4 gennaio 2029

Completamento dello studio (Stimato)

4 gennaio 2029

Date di iscrizione allo studio

Primo inviato

25 gennaio 2021

Primo inviato che soddisfa i criteri di controllo qualità

25 gennaio 2021

Primo Inserito (Effettivo)

28 gennaio 2021

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

27 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

23 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 1026-003
  • MK-1026-003 (Altro identificatore: MSD)
  • 2020-002324-36 (Numero EudraCT)
  • U1111-1290-4004 (Identificatore di registro: UTN)
  • 2023-504931-42-00 (Identificatore di registro: EU CT)
  • 2023 (Sovvenzione/contratto NIH degli Stati Uniti)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .